FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01133990
- Locations
- 🇮🇳
Shatabdi Hospital, Nashik, India
🇮🇳Noble Hospital, Pune, India
🇮🇳Subodh Mitra Cancer Hospital and Research centre, Kolkata, India
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01133756
- Locations
- 🇺🇸
Texas Oncology - Austin Central, Austin, Texas, United States
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT01133977
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT01127438
- Locations
- 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Miami Research Associates, South Miami, Florida, United States
🇺🇸Research Associates of New York, LLP, New York, New York, United States
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01127178
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01127451
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01126736
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01126749
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT01111461
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT01104155
© Copyright 2024. All Rights Reserved by MedPath